##FILTER=off-target=Variant marked as 'off-target'.
##ANALYSISTYPE=GERMLINE_MULTISAMPLE
##PIPELINE=megSAP 0.1-893-ga055b8e
##SAMPLE=<ID=GS140127_01,Gender=male,ExternalSampleName=131787,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=affected>
##SAMPLE=<ID=GS140550_01,Gender=male,ExternalSampleName=131751,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=control>
##SAMPLE=<ID=GS140549_01,Gender=female,ExternalSampleName=131752,IsTumor=no,IsFFPE=no,DiseaseGroup=n/a,DiseaseStatus=control>
##DESCRIPTION=GS140127_01=genotype of sample GS140127_01
##DESCRIPTION=GS140550_01=genotype of sample GS140550_01
##DESCRIPTION=GS140549_01=genotype of sample GS140549_01
##DESCRIPTION=filter=Annotations for filtering and ranking variants.
##DESCRIPTION=quality=Quality parameters - SNP quality (QUAL), depth (DP), allele frequency (AF), mean mapping quality of alternate allele (MQM).
##DESCRIPTION=gene=Affected gene list (comma-separated).
##DESCRIPTION=variant_type=Variant type.
##DESCRIPTION=coding_and_splicing=Coding and splicing details (Gene, ENST number, type, impact, exon/intron number, HGVS.c, HGVS.p, Pfam domain).
##DESCRIPTION=OMIM=OMIM database annotation.
##DESCRIPTION=ClinVar=ClinVar database annotation.
##DESCRIPTION=HGMD=HGMD database annotation.
##DESCRIPTION=RepeatMasker=RepeatMasker annotation.
##DESCRIPTION=dbSNP=Identifier in dbSNP database.
##DESCRIPTION=1000g=Allele frequency in 1000 genomes project.
##DESCRIPTION=gnomAD=Allele frequency in gnomAD project.
##DESCRIPTION=gnomAD_hom_hemi=Homoyzgous counts and hemizygous counts of gnomAD project (genome data).
##DESCRIPTION=gnomAD_sub=Sub-population allele frequenciens (AFR,AMR,EAS,NFE,SAS) in gnomAD project.
##DESCRIPTION=ESP_sub=Sub-population allele frequency (EA,AA) in NHLBI Exome Sequencing project.
##DESCRIPTION=phyloP=phyloP (100way vertebrate) annotation. Deleterious threshold > 1.6.
##DESCRIPTION=Sift=Sift effect prediction for each transcript: D=damaging, T=tolerated.
##DESCRIPTION=PolyPhen=PolyPhen (humVar) effect prediction for each transcript: D=probably damaging, P=possibly damaging, B=benign.
##DESCRIPTION=fathmm-MKL=fathmm-MKL score (for coding/non-coding regions). Deleterious threshold > 0.5.
##DESCRIPTION=CADD=CADD pathogenicity prediction scores (scaled phred-like). Deleterious threshold > 15-20.
##DESCRIPTION=REVEL=REVEL pathogenicity prediction score. Deleterious threshold > 0.5.
##DESCRIPTION=MaxEntScan=MaxEntScan splicing prediction (difference in percent/reference bases score/alternate bases score).
##DESCRIPTION=GeneSplicer=GeneSplicer splicing prediction (state/type/coordinates/confidence/score).
##DESCRIPTION=dbscSNV=dbscSNV splicing prediction (ADA/RF score).
##DESCRIPTION=COSMIC=COSMIC somatic variant database anntotation.
##FILTER=gene_blacklist=The gene(s) are contained on the blacklist of unreliable genes.
#chr	start	end	ref	obs	GS140127_01	GS140550_01	GS140549_01	filter	quality	gene	variant_type	coding_and_splicing	OMIM	ClinVar	HGMD	RepeatMasker	dbSNP	1000g	gnomAD	gnomAD_hom_hemi	gnomAD_sub	ESP_sub	phyloP	Sift	PolyPhen	fathmm-MKL	CADD	REVEL	MaxEntScan	GeneSplicer	dbscSNV	COSMIC
chr1	957898	957898	G	T	hom	het	hom	off-target	QUAL=3685;DP=63,55,45;AF=0.98,0.64,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon2/35:c.463+56G>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799064	0.3285	0.3620	2049,			-2.0720			0.00,0.12	0.04					
chr1	977330	977330	T	C	hom	hom	hom		QUAL=1743;DP=13,26,20;AF=1.00,1.00,1.00;MQM=60	AGRN	splice_region&intron	AGRN:ENST00000379370:splice_region_variant&intron_variant:LOW:exon6/35:c.1178-6T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128292 [benign DISEASE=not specified];			rs2799066	0.8852	0.9235	11978,	0.7093,0.9513,0.9998,0.9177,0.9528	0.9208,0.7194	-0.8450			0.01,0.17	0.11		+2.00% (6.81>6.94)		0.000/0.002	
chr1	977570	977570	G	A	hom	hom	hom	off-target	QUAL=1504;DP=17,21,15;AF=1.00,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon7/35:c.1384+28G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263159 [benign DISEASE=not specified];			rs2710876	0.7941	0.8978	10431,	0.4341,0.9314,0.9725,0.9148,0.9448	0.9196,0.4860	-1.5510			0.03,0.18	0.08					
chr1	978604	978605	CT	-	wt	het	wt	off-target	QUAL=1582;DP=60,194,167;AF=0.00,0.49,0.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon7/35:c.1385-15_1385-14del::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263160 [benign DISEASE=not specified];			rs35881187	0.4792	0.5516	3546,	0.0925,0.6978,0.7848,0.5381,0.5459	0.5470,0.1127	0.0350				0.14					
chr1	981087	981087	A	G	hom	hom	hom	off-target	QUAL=5679;DP=66,65,51;AF=1.00,1.00,1.00;MQM=59	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon14/35:c.2537-26A>G::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263172 [benign DISEASE=not specified];			rs3128098	0.8694	0.9210	11668,	0.6343,0.9463,0.9998,0.9245,0.9550	0.9270,0.6468	-0.5730			0.04,0.15	-0.11					
chr1	981931	981931	A	G	hom	hom	hom		QUAL=6156;DP=49,96,70;AF=1.00,1.00,1.00;MQM=60	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon18/36:c.3066A>G:p.Ser1022=:	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128297 [benign DISEASE=not specified];			rs2465128	0.7977	0.8872	10542,	0.4965,0.9296,0.9679,0.9055,0.8882	0.9098,0.5268	-1.7540			0.02,0.07	-0.59					
chr1	982941	982941	T	C	hom	hom	hom	off-target	QUAL=9172;DP=47,149,105;AF=1.00,1.00,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon20/35:c.3517-12T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263181 [benign DISEASE=not specified];			rs3128102		0.8967	10551,	0.4483,0.9319,0.9724,0.9131,0.9441	0.9154,0.4762	0.1090			0.03,0.17	0.01		-8.10% (6.84>6.29)		0.000/0.014	
chr1	982994	982994	T	C	hom	hom	hom		QUAL=15338;DP=135,208,143;AF=0.99,1.00,1.00;MQM=59	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon21/36:c.3558T>C:p.Phe1186=:PF01390	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128302 [benign DISEASE=not specified];			rs10267	0.8359	0.9089	11057,	0.5239,0.9387,0.9994,0.9164,0.9525	0.9187,0.5422	0.5010			0.09,0.93	0.13					
chr1	984302	984302	T	C	het	hom	wt		QUAL=574;DP=9,19,17;AF=0.67,1.00,0.00;MQM=60	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon24/36:c.4161T>C:p.Thr1387=:	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128307 [benign DISEASE=not specified];			rs9442391	0.5457	0.5885	3980,	0.2706,0.7058,0.8200,0.5656,0.5592	0.5494,0.2794	-1.1240			0.01,0.16	-0.55					
chr1	985266	985266	C	T	het	hom	wt	off-target	QUAL=583;DP=8,20,11;AF=0.50,1.00,0.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon26/35:c.4745-17C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263188 [benign DISEASE=not specified];			rs2275813	0.4952	0.5574	3503,	0.1472,0.7104,0.8105,0.5355,0.5451	0.5278,0.1584	1.9730			0.19,0.18	-0.15		-1.80% (11.49>11.28)			
chr1	985444	985444	G	-	hom	wt	hom	off-target	QUAL=382;DP=4,6,10;AF=0.75,0.50,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+41del::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs774490460		0.5601	3718,	0.7412,0.5298,0.6492,0.4562,0.4874		0.1170				0.19					
chr1	985449	985449	G	A	wt	hom	wt	off-target	QUAL=382;DP=4,6,10;AF=0.75,0.50,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+32G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263192 [benign DISEASE=not specified];			rs2799067	0.5256	0.5840	2213,	0.2597,0.5478,0.5024,0.6195,0.6166		0.1530			0.03,0.07	-0.49					
chr1	985450	985450	G	A	hom	wt	hom	off-target	QUAL=382;DP=4,6,10;AF=0.75,0.50,1.00;MQM=60	AGRN	intron	AGRN:ENST00000379370:intron_variant:MODIFIER:exon27/35:c.4879+33G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs397834473	0.4465	0.5110	3808,	0.6967,0.4835,0.6049,0.4296,0.4499		-0.4470			0.15,0.26	0.34					
chr1	987200	987200	C	T	hom	hom	hom		QUAL=10516;DP=63,150,134;AF=0.97,0.99,1.00;MQM=60	AGRN	splice_region&intron	AGRN:ENST00000379370:splice_region_variant&intron_variant:LOW:exon33/35:c.5651+5C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128317 [benign DISEASE=not specified];			rs9803031	0.7887	0.8880	10551,	0.4376,0.9322,0.9957,0.9078,0.8828	0.9100,0.4580	-0.9360			0.02,0.14	-0.33		-9.47% (9.65>8.73)		0.000/0.016	
chr1	990280	990280	C	T	wt	het	het		QUAL=4766;DP=101,207,174;AF=0.00,0.59,0.51;MQM=60	AGRN	synonymous	AGRN:ENST00000379370:synonymous_variant:LOW:exon36/36:c.6057C>T:p.Asp2019=:PF00054	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	128319 [benign DISEASE=not specified];			rs4275402		0.6766	5679,	0.3087,0.7713,0.8130,0.6980,0.6132	0.7054,0.3322	-0.7110			0.35,0.88	0.85					
chr1	990380	990380	C	T	hom	het	het		QUAL=12409;DP=162,432,332;AF=0.98,0.49,0.44;MQM=60	AGRN	3'UTR	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*19C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];	263157 [benign DISEASE=not specified];			rs3121561	0.3434	0.3626	2172,	0.5220,0.2146,0.1801,0.2917,0.3088	0.2722,0.4760	-0.1240			0.05,0.09	-0.59					
chr1	990417	990417	T	C	hom	het	het		QUAL=16506;DP=185,502,389;AF=0.99,0.49,0.46;MQM=60	AGRN,RP11-54O7.14	3'UTR,non_coding_transcript_exon	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*56T>C::,RP11-54O7.14:ENST00000418300:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.5T>C::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2465136	0.3840	0.3948	2673,			0.3020			0.78,0.96	0.91					
chr1	990517	990517	C	T	hom	hom	het		QUAL=18325;DP=120,372,285;AF=0.99,1.00,0.48;MQM=60	AGRN,RP11-54O7.14	3'UTR,non_coding_transcript_exon	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*156C>T::,RP11-54O7.14:ENST00000418300:non_coding_transcript_exon_variant:MODIFIER:exon1/2:n.105C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2710872	0.9179	0.8780	11952,			-0.4100			0.04,0.14	0.06					
chr1	990773	990773	C	T	hom	hom	het		QUAL=22302;DP=180,404,296;AF=1.00,1.00,0.54;MQM=60	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*412C>T::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.183+178C>T::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799072	0.8460	0.8194	10554,			-0.5960			0.05,0.13	-0.05					
chr1	990806	990806	G	A	hom	hom	het		QUAL=24526;DP=222,450,312;AF=0.98,1.00,0.54;MQM=60	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*445G>A::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.183+211G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs2799073	0.8462	0.8196	10553,			-0.1840			0.06,0.14	0.21					
chr1	990984	990984	G	A	hom	hom	het		QUAL=15841;DP=146,273,190;AF=1.00,1.00,0.59;MQM=59	AGRN,RP11-54O7.14	3'UTR,intron&non_coding_transcript	AGRN:ENST00000379370:3_prime_UTR_variant:MODIFIER:exon36/36:c.*623G>A::,RP11-54O7.14:ENST00000418300:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.184-294G>A::	103320 [AGRN (provisional) Myasthenic syndrome,congenital,8,with pre- and postsynaptic defects,615120];				rs8014	0.9223	0.8818	12061,			-2.5600			0.00,0.06	-0.19					
chr1	1956362	1956362	G	A	hom	het	het	off-target	QUAL=6515;DP=81,170,172;AF=1.00,0.48,0.49;MQM=60	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon1/8:c.69-19G>A::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256824 [benign DISEASE=not specified];			rs2376805	0.7756	0.8126	10214,	0.7943,0.7390,0.7175,0.8311,0.7724	0.8329,0.7939	-0.2280			0.00,0.15	-0.17		-19.11% (7.68>6.22)			
chr1	1957037	1957037	T	C	het	het	wt		QUAL=6704;DP=159,399,341;AF=0.53,0.49,0.00;MQM=59	GABRD	synonymous	GABRD:ENST00000378585:synonymous_variant:LOW:exon4/9:c.330T>C:p.Gly110=:PF02931	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256823 [benign DISEASE=not specified];			rs2229110	0.5613	0.6471	6566,	0.7308,0.4730,0.3125,0.6570,0.4739	0.6605,0.7308	-1.3800			0.07,0.88	1.61					
chr1	1957220	1957220	G	-	het	het	wt	off-target	QUAL=1338;DP=56,79,56;AF=0.52,0.49,0.00;MQM=60	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon4/8:c.470+45del::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];				rs3831907	0.1080	0.1195	280,	0.2115,0.0547,0.0254,0.1143,0.0775	0.1236,0.2055	-4.7340				-0.40					
chr1	1960674	1960674	C	T	het	wt	het		QUAL=4896;DP=119,386,266;AF=0.50,0.01,0.56;MQM=59	GABRD	synonymous	GABRD:ENST00000378585:synonymous_variant:LOW:exon7/9:c.816C>T:p.Ser272=:PF02932	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256825 [benign DISEASE=not specified];			rs28408173	0.1983	0.1923	424,	0.0311,0.2388,0.4728,0.1437,0.2548	0.1313,0.0322	-0.7780			0.10,0.96	0.19					
chr1	1961408	1961408	C	T	het	wt	het	off-target	QUAL=1606;DP=69,74,64;AF=0.57,0.01,0.50;MQM=59	GABRD	intron	GABRD:ENST00000378585:intron_variant:MODIFIER:exon8/8:c.1060-14C>T::	137163 [GABRD (confirmed) Epilepsy,generalized,with febrile seizures plus,type 5,susceptibility to,613060/Epilepsy,idiopathic generalized,10,613060/Epilepsy,juvenile myoclonic,susceptibility to,613060];	256822 [benign DISEASE=not specified];			rs28431879	0.1999	0.1852	442,	0.0291,0.2374,0.4842,0.1370,0.2434	0.1288,0.0323	-1.4010			0.00,0.11	-0.45		-8.69% (7.60>6.94)			
chr1	2337277	2337277	C	T	het	wt	wt		QUAL=107;DP=20,1,1;AF=0.40,0.00,0.00;MQM=60	PEX10	splice_region&intron,intron	PEX10:ENST00000288774:splice_region_variant&intron_variant:LOW:exon5/5:c.973-4G>A::,PEX10:ENST00000447513:splice_region_variant&intron_variant:LOW:exon5/5:c.913-4G>A::,PEX10:ENST00000507596:intron_variant:MODIFIER:exon5/5:c.913-10G>A::	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];	262791 [likely benign DISEASE=Zellweger syndrome,not specified];			rs11586985	0.0809	0.1049	161,	0.0217,0.0579,0.1205,0.1219,0.1097	0.1113,0.0247	-1.9740			0.08,0.13	-0.22		-1.66% (13.68>13.46),-0.10% (-18.78>-18.77)		0.000/0.002	
chr1	2338126	2338126	C	A	wt	het	het	off-target	QUAL=1048;DP=46,55,45;AF=0.00,0.49,0.49;MQM=60	PEX10	intron	PEX10:ENST00000288774:intron_variant:MODIFIER:exon4/5:c.836+33G>T::,PEX10:ENST00000447513:intron_variant:MODIFIER:exon4/5:c.776+33G>T::,PEX10:ENST00000507596:intron_variant:MODIFIER:exon4/5:c.776+33G>T::	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];				rs3795269	0.3391	0.4032	2537,	0.2885,0.4080,0.2646,0.4332,0.3650	0.4278,0.2942	0.5730			0.20,0.15	0.16					
chr1	2340200	2340200	T	C	wt	het	het		QUAL=985;DP=43,48,39;AF=0.02,0.54,0.44;MQM=60	PEX10	synonymous	PEX10:ENST00000288774:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757,PEX10:ENST00000447513:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757,PEX10:ENST00000507596:synonymous_variant:LOW:exon3/6:c.291A>G:p.Thr97=:PF04757	602859 [PEX10 (confirmed) Peroxisome biogenesis disorder 6A (Zellweger),614870/Peroxisome biogenesis disorder 6B,614871];	129884 [benign DISEASE=Zellweger syndrome,not specified];			rs2494598		0.7743	8515,	0.5896,0.7707,0.7203,0.8113,0.7253	0.8170,0.6010	-6.5230			0.03,0.05	-0.74					
chr1	5922834	5922834	C	A	het	hom	wt	off-target	QUAL=1543;DP=54,42,26;AF=0.37,1.00,0.00;MQM=60	NPHP4,MIR4689	downstream_gene,upstream_gene	NPHP4:ENST00000378156:downstream_gene_variant:MODIFIER::::,MIR4689:ENST00000582517:upstream_gene_variant:MODIFIER::::					rs12133533	0.0966	0.1242	299,	0.0176,0.0839,0.0531,0.1639,0.1088		-0.3700			0.06,0.16	-0.15					
chr1	5926507	5926507	T	C	het	hom	wt		QUAL=8832;DP=275,182,155;AF=0.49,0.99,0.00;MQM=60	NPHP4	synonymous	NPHP4:ENST00000378156:synonymous_variant:LOW:exon26/30:c.3570A>G:p.Glu1190=:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95683 [benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs555164	0.3197	0.3935	2128,	0.2006,0.3708,0.2574,0.4226,0.4305	0.4197,0.1984	0.2880			0.02,0.92	1.09					
chr1	5927031	5927031	A	G	het	hom	wt	off-target	QUAL=3708;DP=80,96,66;AF=0.48,1.00,0.00;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon25/29:c.3558+59T>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];				rs12122135	0.1028	0.1252	294,			-0.2430			0.02,0.10	-0.28					
chr1	5927943	5927943	G	A	wt	het	wt		QUAL=3628;DP=131,360,269;AF=0.00,0.48,0.00;MQM=60	NPHP4	missense	NPHP4:ENST00000378156:missense_variant:MODERATE:exon24/30:c.3329C>T:p.Ala1110Val:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95682 [conflicting interpretations of pathogenicity DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];	CM125782 [CLASS=DM MUT=ALT PHEN="Cardiovascular malformations" GENE=NPHP4];		rs139767853	0.0014	0.0037	0,	0.0012,0.0029,0.0000,0.0061,0.0008	0.0067,0.0009	0.0280	T	B	0.08,0.26	0.24	0.32				
chr1	5934490	5934490	A	G	hom	hom	het	off-target	QUAL=5950;DP=74,112,68;AF=0.99,1.00,0.49;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon22/29:c.3231+41T>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260554 [benign DISEASE=not specified];			rs868163	0.5693	0.6451	6545,	0.7139,0.5001,0.2710,0.6459,0.6154	0.6523,0.7142	-3.6260			0.01,0.09	-0.33					
chr1	5935162	5935162	A	T	het	het	hom		QUAL=4956;DP=87,128,87;AF=0.38,0.52,1.00;MQM=60	NPHP4	splice_acceptor	NPHP4:ENST00000378156:splice_acceptor_variant:HIGH:exon20/29:c.2818-2T>A::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	167375 [benign DISEASE=not specified];			rs1287637	0.8433	0.8615	11463,	0.8944,0.7946,0.8109,0.8252,0.8290	0.8172,0.8938	0.4530			0.00,0.85	2.49		+927.16% (0.90>9.27)			
chr1	5937391	5937391	C	T	hom	hom	wt	off-target	QUAL=157;DP=1,4,87;AF=1.00,1.00,1.00;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon19/29:c.2612-33G>A::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260547 [benign DISEASE=not specified];			rs3747989	0.8327	0.8286	10687,	0.9386,0.7300,0.8509,0.8009,0.7366	0.8107,0.9323	-2.2310			0.00,0.05	-0.36					
chr1	5947308	5947308	G	A	wt	het	wt	off-target	QUAL=1780;DP=130,187,146;AF=0.00,0.42,0.01;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon18/29:c.2485+38C>T::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	260546 [benign DISEASE=not specified];			rs41280814	0.0863	0.1346	252,	0.0277,0.0784,0.0806,0.1719,0.1163	0.1732,0.0294	-1.8090			0.05,0.17	-0.08					
chr1	5965381	5965381	C	T	wt	het	wt		QUAL=2692;DP=208,262,206;AF=0.00,0.43,0.00;MQM=60	NPHP4	synonymous	NPHP4:ENST00000378156:synonymous_variant:LOW:exon15/30:c.1926G>A:p.Glu642=:	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95673 [benign/likely benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs12120967	0.0841	0.1320	251,	0.0274,0.0764,0.0770,0.1673,0.1132	0.1765,0.0297	-0.7650			0.03,0.33	-0.10					
chr1	5987696	5987696	T	C	wt	het	wt	off-target	QUAL=2405;DP=136,184,150;AF=0.00,0.54,0.02;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon11/29:c.1441+13A>G::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];	95671 [benign/likely benign DISEASE=Nephronophthisis,Renal dysplasia and retinal aplasia,not specified];			rs7520105	0.1412	0.1687	420,	0.2101,0.0873,0.0772,0.1683,0.1156	0.1769,0.1985	0.8260			0.31,0.17	0.40					
chr1	6046432	6046432	C	G	wt	het	wt	off-target	QUAL=789;DP=53,52,46;AF=0.00,0.63,0.02;MQM=60	NPHP4	intron	NPHP4:ENST00000378156:intron_variant:MODIFIER:exon1/29:c.-38-45G>C::	607215 [NPHP4 (provisional) Nephronophthisis 4,606966/Senior-Loken syndrome 4,606996];				rs1295111	0.3878	0.4118	2640,			-0.1940			0.09,0.19	-0.05					
chr1	6052571	6052571	G	A	wt	het	wt	off-target	QUAL=398;DP=3,39,29;AF=0.00,0.51,0.00;MQM=60	KCNAB2	5'UTR,intron	KCNAB2:ENST00000378097:5_prime_UTR_variant:MODIFIER:exon1/16:c.-330G>A::,KCNAB2:ENST00000378111:intron_variant:MODIFIER:exon1/7:c.-53+955G>A::					rs61760765	0.0218	0.0350	27,			-0.2790			0.16,0.33	0.61					
chr1	6052581	6052581	G	A	hom	hom	het	off-target	QUAL=1351;DP=2,34,28;AF=1.00,1.00,0.68;MQM=60	KCNAB2	5'UTR,intron	KCNAB2:ENST00000378097:5_prime_UTR_variant:MODIFIER:exon1/16:c.-320G>A::,KCNAB2:ENST00000378111:intron_variant:MODIFIER:exon1/7:c.-53+965G>A::					rs806109	0.9024	0.8323	10792,			0.0500			0.10,0.21	0.47					
chr1	6526183	6526183	G	A	het	het	wt		QUAL=374;DP=14,20,5;AF=0.43,0.70,0.00;MQM=59	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1440C>T::,TNFRSF25:ENST00000351959:5_prime_UTR_variant:MODIFIER:exon1/9:c.-16C>T::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-16C>T::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1440C>T::,TNFRSF25:ENST00000377782:5_prime_UTR_variant:MODIFIER:exon1/10:c.-16C>T::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1440C>T::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297904 [benign DISEASE=Distal spinal muscular atrophy];			rs3007417	0.2023	0.1849	1067,	0.5065,0.0514,0.0000,0.0711,0.0791	0.0577,0.3759	-0.6580			0.06,0.14	0.41					
chr1	6526203	6526210	CGTGCTCT	-	het	het	wt		QUAL=369;DP=11,21,6;AF=0.55,0.67,0.00;MQM=59	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1413_*1420del::,TNFRSF25:ENST00000351959:5_prime_UTR_variant:MODIFIER:exon1/9:c.-43_-36del::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-43_-36del::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1413_*1420del::,TNFRSF25:ENST00000377782:5_prime_UTR_variant:MODIFIER:exon1/10:c.-43_-36del::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1413_*1420del::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297905 [benign DISEASE=Distal spinal muscular atrophy];			rs45616733	0.2027	0.1845	1053,	0.4307,0.0470,0.0000,0.0586,0.0691	0.0512,0.3970	0.8620				0.57					
chr1	6526241	6526244	CGCC	-	hom	het	wt		QUAL=315;DP=5,15,3;AF=1.00,0.73,0.00;MQM=60	PLEKHG5,TNFRSF25	3'UTR,5'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1379_*1382del::,TNFRSF25:ENST00000356876:5_prime_UTR_variant:MODIFIER:exon1/10:c.-77_-74del::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1379_*1382del::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1379_*1382del::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297906 [benign DISEASE=Distal spinal muscular atrophy];			rs45542640	0.2025	0.1844	1072,		0.0517,0.4246	1.0930				0.25					
chr1	6526319	6526319	C	T	het	het	wt		QUAL=293;DP=31,33,30;AF=0.35,0.39,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1304G>A::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1304G>A::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1304G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297910 [likely benign DISEASE=Distal spinal muscular atrophy];			rs45604837	0.0863	0.0837	162,			-0.5600			0.05,0.16	0.14					
chr1	6526465	6526465	C	G	het	het	wt		QUAL=3430;DP=81,199,150;AF=0.48,0.54,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1158G>C::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*1158G>C::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1158G>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297912 [benign DISEASE=Distal spinal muscular atrophy];		MIR3	rs2986754	0.2043	0.1820	1156,			-0.5720			0.01,0.10	-0.12					
chr1	6527333	6527333	A	G	het	het	wt		QUAL=1564;DP=75,59,53;AF=0.51,0.47,0.00;MQM=60	PLEKHG5	3'UTR	PLEKHG5:ENST00000340850:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377725:3_prime_UTR_variant:MODIFIER:exon22/22:c.*318T>C::,PLEKHG5:ENST00000377728:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377732:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000377737:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000377740:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000377748:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000400913:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::,PLEKHG5:ENST00000400915:3_prime_UTR_variant:MODIFIER:exon22/22:c.*290T>C::,PLEKHG5:ENST00000535355:3_prime_UTR_variant:MODIFIER:exon21/21:c.*290T>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297928 [benign DISEASE=Distal spinal muscular atrophy];			rs14708	0.2670	0.2637	1687,			2.0370			0.00,0.11	0.75					
chr1	6529183	6529185	TCC	-	wt	het	wt		QUAL=667;DP=53,109,66;AF=0.38,0.46,0.05;MQM=60	PLEKHG5	inframe_deletion	PLEKHG5:ENST00000340850:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377725:inframe_deletion:MODERATE:exon19/22:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377728:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377732:inframe_deletion:MODERATE:exon19/21:c.2277_2279del:p.Glu760del:,PLEKHG5:ENST00000377737:inframe_deletion:MODERATE:exon20/22:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000377740:inframe_deletion:MODERATE:exon20/22:c.2397_2399del:p.Glu800del:,PLEKHG5:ENST00000377748:inframe_deletion:MODERATE:exon20/22:c.2397_2399del:p.Glu800del:,PLEKHG5:ENST00000400913:inframe_deletion:MODERATE:exon19/21:c.2166_2168del:p.Glu723del:,PLEKHG5:ENST00000400915:inframe_deletion:MODERATE:exon20/22:c.2334_2336del:p.Glu779del:,PLEKHG5:ENST00000535355:inframe_deletion:MODERATE:exon19/21:c.2373_2375del:p.Glu792del:,PLEKHG5:ENST00000537245:inframe_deletion:MODERATE:exon20/22:c.2403_2405del:p.Glu802del:,PLEKHG5:ENST00000544978:inframe_deletion:MODERATE:exon20/22:c.2166_2168del:p.Glu723del:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	194979 [benign/likely benign DISEASE=Distal spinal muscular atrophy,not specified];		(TCC)n	rs113541584	0.0972	0.0841	133,	0.1909,0.0571,0.0088,0.0753,0.0955	0.1205,0.2668	0.1060				0.86					COSM4590012,COSM4590013,COSM911543
chr1	6529443	6529443	A	G	het	het	wt		QUAL=9602;DP=320,486,391;AF=0.48,0.48,0.00;MQM=60	PLEKHG5	synonymous	PLEKHG5:ENST00000340850:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377725:synonymous_variant:LOW:exon18/22:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377728:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377732:synonymous_variant:LOW:exon18/21:c.2112T>C:p.Ser704=:,PLEKHG5:ENST00000377737:synonymous_variant:LOW:exon19/22:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000377740:synonymous_variant:LOW:exon19/22:c.2232T>C:p.Ser744=:,PLEKHG5:ENST00000377748:synonymous_variant:LOW:exon19/22:c.2232T>C:p.Ser744=:,PLEKHG5:ENST00000400913:synonymous_variant:LOW:exon18/21:c.2001T>C:p.Ser667=:,PLEKHG5:ENST00000400915:synonymous_variant:LOW:exon19/22:c.2169T>C:p.Ser723=:,PLEKHG5:ENST00000535355:synonymous_variant:LOW:exon18/21:c.2208T>C:p.Ser736=:,PLEKHG5:ENST00000537245:synonymous_variant:LOW:exon19/22:c.2238T>C:p.Ser746=:,PLEKHG5:ENST00000544978:synonymous_variant:LOW:exon19/22:c.2001T>C:p.Ser667=:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	194881 [benign DISEASE=Distal spinal muscular atrophy,not specified];			rs730600	0.2696	0.2653	1708,	0.5957,0.0929,0.0044,0.1427,0.1768	0.1403,0.5738	-0.2200			0.08,0.79	1.36					
chr1	6530435	6530435	A	G	het	het	wt	off-target	QUAL=1079;DP=39,55,49;AF=0.46,0.53,0.00;MQM=60	PLEKHG5	intron	PLEKHG5:ENST00000340850:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000377725:intron_variant:MODIFIER:exon15/21:c.1681-20T>C::,PLEKHG5:ENST00000377728:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000377732:intron_variant:MODIFIER:exon15/20:c.1792-20T>C::,PLEKHG5:ENST00000377737:intron_variant:MODIFIER:exon16/21:c.1681-20T>C::,PLEKHG5:ENST00000377740:intron_variant:MODIFIER:exon16/21:c.1912-20T>C::,PLEKHG5:ENST00000377748:intron_variant:MODIFIER:exon16/21:c.1912-20T>C::,PLEKHG5:ENST00000400913:intron_variant:MODIFIER:exon15/20:c.1681-20T>C::,PLEKHG5:ENST00000400915:intron_variant:MODIFIER:exon16/21:c.1849-20T>C::,PLEKHG5:ENST00000535355:intron_variant:MODIFIER:exon15/20:c.1888-20T>C::,PLEKHG5:ENST00000537245:intron_variant:MODIFIER:exon16/21:c.1918-20T>C::,PLEKHG5:ENST00000544978:intron_variant:MODIFIER:exon16/21:c.1681-20T>C::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs2986753	0.1717	0.1807	630,	0.3439,0.0768,0.0042,0.1305,0.1520	0.1273,0.3334	-0.4640			0.01,0.12	0.22		-0.43% (7.80>7.76)			
chr1	6530965	6530965	-	G	hom	hom	hom	off-target	QUAL=6161;DP=43,126,96;AF=0.93,0.99,0.95;MQM=59	PLEKHG5	intron	PLEKHG5:ENST00000340850:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000377725:intron_variant:MODIFIER:exon13/21:c.1393-22dup::,PLEKHG5:ENST00000377728:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000377732:intron_variant:MODIFIER:exon13/20:c.1504-22dup::,PLEKHG5:ENST00000377737:intron_variant:MODIFIER:exon14/21:c.1393-22dup::,PLEKHG5:ENST00000377740:intron_variant:MODIFIER:exon14/21:c.1624-22dup::,PLEKHG5:ENST00000377748:intron_variant:MODIFIER:exon14/21:c.1624-22dup::,PLEKHG5:ENST00000400913:intron_variant:MODIFIER:exon13/20:c.1393-22dup::,PLEKHG5:ENST00000400915:intron_variant:MODIFIER:exon14/21:c.1561-22dup::,PLEKHG5:ENST00000535355:intron_variant:MODIFIER:exon13/20:c.1600-22dup::,PLEKHG5:ENST00000537245:intron_variant:MODIFIER:exon14/21:c.1630-22dup::,PLEKHG5:ENST00000544978:intron_variant:MODIFIER:exon14/21:c.1393-22dup::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs111312565	1.0000	1.0000	15287,	1.0000,1.0000,0.9999,1.0000,1.0000	0.9927,0.9948					0.05					
chr1	6531589	6531589	C	T	het	het	wt		QUAL=1652;DP=36,114,115;AF=0.67,0.45,0.00;MQM=60	PLEKHG5	missense	PLEKHG5:ENST00000340850:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377725:missense_variant:MODERATE:exon12/22:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377728:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377732:missense_variant:MODERATE:exon12/21:c.1351G>A:p.Ala451Thr:PF00621,PLEKHG5:ENST00000377737:missense_variant:MODERATE:exon13/22:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon13/22:c.1471G>A:p.Ala491Thr:PF00621,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon13/22:c.1471G>A:p.Ala491Thr:PF00621,PLEKHG5:ENST00000400913:missense_variant:MODERATE:exon12/21:c.1240G>A:p.Ala414Thr:PF00621,PLEKHG5:ENST00000400915:missense_variant:MODERATE:exon13/22:c.1408G>A:p.Ala470Thr:PF00621,PLEKHG5:ENST00000535355:missense_variant:MODERATE:exon12/21:c.1447G>A:p.Ala483Thr:PF00621,PLEKHG5:ENST00000537245:missense_variant:MODERATE:exon13/22:c.1477G>A:p.Ala493Thr:PF00621,PLEKHG5:ENST00000544978:missense_variant:MODERATE:exon13/22:c.1240G>A:p.Ala414Thr:PF00621	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	297959 [likely benign DISEASE=Distal spinal muscular atrophy];			rs74809741	0.0553	0.0573	68,	0.0876,0.0366,0.0002,0.0594,0.0522	0.0575,0.0878	0.6400	T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B,B	0.73,0.93	1.48	0.04				
chr1	6533393	6533393	G	C	het	het	wt		QUAL=479;DP=25,25,19;AF=0.44,0.56,0.00;MQM=60	PLEKHG5	missense	PLEKHG5:ENST00000340850:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377725:missense_variant:MODERATE:exon8/22:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377728:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377732:missense_variant:MODERATE:exon8/21:c.824C>G:p.Thr275Ser:,PLEKHG5:ENST00000377737:missense_variant:MODERATE:exon9/22:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon9/22:c.944C>G:p.Thr315Ser:,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon9/22:c.944C>G:p.Thr315Ser:,PLEKHG5:ENST00000400913:missense_variant:MODERATE:exon8/21:c.713C>G:p.Thr238Ser:,PLEKHG5:ENST00000400915:missense_variant:MODERATE:exon9/22:c.881C>G:p.Thr294Ser:,PLEKHG5:ENST00000535355:missense_variant:MODERATE:exon8/21:c.920C>G:p.Thr307Ser:,PLEKHG5:ENST00000537245:missense_variant:MODERATE:exon9/22:c.950C>G:p.Thr317Ser:,PLEKHG5:ENST00000544978:missense_variant:MODERATE:exon9/22:c.713C>G:p.Thr238Ser:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	198895 [benign DISEASE=Distal spinal muscular atrophy,not specified];			rs61741379	0.2857	0.2792	1990,	0.6476,0.0988,0.0073,0.1413,0.1629	0.1280,0.5571	0.8480	T,T,T,T,T,T,T,T,T,T,T,T	B,B,B,B,B,B,B,B,B,B,B,B	0.00,0.17	-0.22	0.07				
chr1	6579521	6579521	G	C	het	het	het		QUAL=3392;DP=121,91,77;AF=0.53,0.52,0.45;MQM=60	PLEKHG5	5'UTR,missense	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-181C>G::,PLEKHG5:ENST00000377740:missense_variant:MODERATE:exon1/22:c.51C>G:p.Ser17Arg:,PLEKHG5:ENST00000377748:missense_variant:MODERATE:exon1/22:c.51C>G:p.Ser17Arg:	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs17438786	0.0136	0.0245	11,	0.0052,0.0165,0.0000,0.0327,0.0181	0.0301,0.0062	0.0870	 ,T,T	 ,B,B	0.13,0.49	0.54	0.09				
chr1	6579607	6579607	C	T	hom	hom	hom		QUAL=20016;DP=179,270,204;AF=1.00,1.00,1.00;MQM=59	PLEKHG5	5'UTR	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-267G>A::,PLEKHG5:ENST00000377740:5_prime_UTR_variant:MODIFIER:exon1/22:c.-36G>A::,PLEKHG5:ENST00000377748:5_prime_UTR_variant:MODIFIER:exon1/22:c.-36G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];	380860 [benign DISEASE=not specified];			rs1556035	0.7460	0.8596	9844,	0.5162,0.9260,0.7940,0.8821,0.8643	0.8862,0.5486	0.2500			0.07,0.20	0.23					
chr1	6579843	6579843	C	T	hom	hom	hom		QUAL=41827;DP=292,585,454;AF=0.99,1.00,1.00;MQM=59	PLEKHG5	5'UTR	PLEKHG5:ENST00000377737:5_prime_UTR_variant:MODIFIER:exon1/22:c.-503G>A::,PLEKHG5:ENST00000377740:5_prime_UTR_variant:MODIFIER:exon1/22:c.-272G>A::,PLEKHG5:ENST00000377748:5_prime_UTR_variant:MODIFIER:exon1/22:c.-272G>A::	611101 [PLEKHG5 (confirmed) Spinal muscular atrophy,distal,autosomal recessive,4,611067/Charcot-Marie-Tooth disease,recessive intermediate C,615376];				rs1010584	0.7354	0.7728	9605,			-0.5650			0.03,0.20	0.18					
chr1	10318652	10318652	C	G	wt	wt	het		QUAL=2875;DP=314,250,229;AF=0.00,0.00,0.50;MQM=60	KIF1B	synonymous	KIF1B:ENST00000263934:synonymous_variant:LOW:exon4/47:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377081:synonymous_variant:LOW:exon3/48:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377083:synonymous_variant:LOW:exon4/21:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377086:synonymous_variant:LOW:exon4/49:c.285C>G:p.Ala95=:PF00225,KIF1B:ENST00000377093:synonymous_variant:LOW:exon4/21:c.285C>G:p.Ala95=:PF00225	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	129399 [benign DISEASE=Pheochromocytoma,Neuroblastoma,not specified,Charcot-Marie-Tooth, Type 2];			rs12402052	0.2300	0.2765	1019,	0.0847,0.3428,0.2909,0.2913,0.2300	0.2969,0.0915	0.0540			0.81,0.97	0.79					
chr1	10322054	10322054	G	A	wt	wt	het	off-target	QUAL=2022;DP=314,272,179;AF=0.00,0.00,0.46;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon5/46:c.429+26G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon4/47:c.429+26G>A::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon5/20:c.429+26G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon5/48:c.429+26G>A::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon5/20:c.429+26G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs4846209	0.3399	0.3514	1911,	0.3424,0.3922,0.3668,0.3434,0.2584	0.3488,0.3323	0.0780			0.00,0.08	0.04					
chr1	10327407	10327407	A	T	wt	wt	het	off-target	QUAL=1115;DP=257,131,100;AF=0.00,0.00,0.50;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon5/46:c.430-31A>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon4/47:c.430-31A>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon5/20:c.430-31A>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon5/48:c.430-31A>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon5/20:c.430-31A>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs12141246	0.3806	0.3772	2218,	0.4135,0.3959,0.4074,0.3428,0.2583	0.3499,0.4094	-1.8450			0.00,0.07	-0.04					
chr1	10328338	10328338	C	T	wt	wt	het	off-target	QUAL=2382;DP=242,187,186;AF=0.00,0.00,0.52;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon7/46:c.720+17C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon6/47:c.720+17C>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon7/20:c.720+17C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon7/48:c.720+17C>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon7/20:c.720+17C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	260542 [benign DISEASE=not specified];			rs1339458	0.2540	0.2815	1086,	0.1539,0.3470,0.2897,0.2916,0.2306	0.2970,0.1530	-1.1960			0.06,0.15	0.18					
chr1	10342629	10342629	G	A	wt	het	het	off-target	QUAL=5605;DP=180,224,219;AF=0.01,0.50,0.49;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon13/46:c.1296+38G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon14/47:c.1434+38G>A::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon13/20:c.1296+38G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon15/48:c.1434+38G>A::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon13/20:c.1296+38G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			L3	rs3748576	0.7127	0.7067	8032,	0.9349,0.7352,0.5300,0.5980,0.6220	0.6030,0.9163	-0.7550			0.01,0.13	0.01					
chr1	10355834	10355834	C	T	wt	wt	het		QUAL=1539;DP=134,158,128;AF=0.01,0.00,0.48;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon17/46:c.1639+10C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon18/47:c.1777+10C>T::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon17/20:c.1639+10C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon19/48:c.1777+10C>T::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon17/20:c.1639+10C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	177960 [benign DISEASE=Pheochromocytoma,Neuroblastoma,not specified,Charcot-Marie-Tooth, Type 2];			rs3753037	0.2640	0.2841	1139,	0.1878,0.3488,0.2905,0.2918,0.2303	0.2970,0.1861	1.0480			0.09,0.20	0.09					
chr1	10357207	10357207	T	-	wt	het	wt	off-target	QUAL=196;DP=183,243,171;AF=0.33,0.30,0.29;MQM=59	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon19/46:c.1905-9del::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon20/47:c.2043-9del::,KIF1B:ENST00000377083:intron_variant:MODIFIER:exon19/20:c.1905-9del::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon21/48:c.2043-9del::,KIF1B:ENST00000377093:intron_variant:MODIFIER:exon19/20:c.1905-9del::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			(T)n	rs199617049		0.4227	0,	0.4280,0.4278,0.4248,0.4265,0.4314		-0.0240				-0.64					
chr1	10366487	10366487	T	G	wt	wt	het		QUAL=2585;DP=248,227,230;AF=0.00,0.00,0.45;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+9183T>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+9183T>G::,KIF1B:ENST00000377083:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1782T>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+9183T>G::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1782T>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs8019	0.3838	0.3972	2435,			0.6540			0.00,0.09	-0.03					
chr1	10366692	10366692	C	G	wt	wt	het		QUAL=2877;DP=288,280,252;AF=0.00,0.00,0.47;MQM=60	KIF1B,RN7SL731P	intron,3'UTR,non_coding_transcript_exon	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+9388C>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+9388C>G::,KIF1B:ENST00000377083:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1987C>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+9388C>G::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*1987C>G::,RN7SL731P:ENST00000584329:non_coding_transcript_exon_variant:MODIFIER:exon1/1:n.170C>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			7SLRNA	rs4623	0.3343	0.3431	1821,			-0.5090			0.00,0.03	0.10					
chr1	10367424	10367424	G	A	wt	wt	het		QUAL=343;DP=114,47,43;AF=0.01,0.00,0.42;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+10120G>A::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+10120G>A::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+10120G>A::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*2719G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			AluSx	rs2004034	0.2316	0.2397	1027,			-0.1060			0.00,0.11	0.06					
chr1	10367591	10367591	T	C	wt	wt	het		QUAL=1134;DP=189,99,87;AF=0.00,0.01,0.59;MQM=60	KIF1B	intron,3'UTR	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon20/46:c.1977+10287T>C::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon21/47:c.2115+10287T>C::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon22/48:c.2115+10287T>C::,KIF1B:ENST00000377093:3_prime_UTR_variant:MODIFIER:exon21/21:c.*2886T>C::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];			AluSx	rs1065828	0.3341	0.3431	1836,			-0.8920			0.00,0.03	0.07					
chr1	10384176	10384176	-	TTGAAA	het	het	het	off-target	QUAL=5259;DP=226,186,143;AF=0.45,0.42,0.45;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon23/46:c.2399+57_2399+58insTGAAAT::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon24/47:c.2537+57_2537+58insTGAAAT::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon25/48:c.2537+57_2537+58insTGAAAT::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs3831405	0.2326	0.2378	946,							0.21					
chr1	10394536	10394536	C	G	het	het	het	off-target	QUAL=8177;DP=248,219,152;AF=0.53,0.53,0.48;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon25/46:c.2787-42C>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon26/47:c.2925-42C>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon27/48:c.2925-42C>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs2276100	0.3339	0.3307	1700,	0.3240,0.3828,0.3666,0.3198,0.2627	0.3271,0.3248	-0.0570			0.09,0.23	0.27					
chr1	10397080	10397080	A	G	wt	het	wt	off-target	QUAL=1131;DP=203,101,79;AF=0.00,0.47,0.00;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon27/46:c.2992-52A>G::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon28/47:c.3130-52A>G::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon29/48:c.3130-52A>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs71643087	0.0112	0.0277	16,		0.0311,0.0063	0.0100			0.01,0.20	0.08					
chr1	10420937	10420937	C	T	het	het	het	off-target	QUAL=11846;DP=259,371,298;AF=0.51,0.49,0.51;MQM=59	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon36/46:c.3918-50C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon37/47:c.4056-50C>T::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon38/48:c.4056-50C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs3748579	0.3341	0.3301	1685,	0.3235,0.3825,0.3663,0.3196,0.2632	0.3267,0.3250	-0.4610			0.01,0.18	-0.03					
chr1	10425118	10425118	T	-	het	het	het	off-target	QUAL=2916;DP=98,113,92;AF=0.47,0.52,0.45;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon39/46:c.4229-33del::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon40/47:c.4367-33del::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon41/48:c.4367-33del::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs34161257	0.5240	0.5248	4293,	0.6615,0.4685,0.3722,0.4751,0.4645		0.5110				0.10					
chr1	10431158	10431158	T	C	het	het	het	off-target	QUAL=7040;DP=219,224,156;AF=0.45,0.53,0.47;MQM=60	KIF1B	intron	KIF1B:ENST00000263934:intron_variant:MODIFIER:exon42/46:c.4687-41T>C::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon43/47:c.4825-41T>C::,KIF1B:ENST00000377086:intron_variant:MODIFIER:exon44/48:c.4825-41T>C::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];				rs17411502	0.2490	0.2838	1098,	0.1490,0.3475,0.2832,0.2956,0.2381	0.3003,0.1548	-0.7390			0.03,0.17	0.75					
chr1	10435324	10435324	C	A	het	het	het		QUAL=7167;DP=295,147,115;AF=0.45,0.52,0.57;MQM=60	KIF1B	synonymous	KIF1B:ENST00000263934:synonymous_variant:LOW:exon46/47:c.5163C>A:p.Thr1721=:PF00169,KIF1B:ENST00000377081:synonymous_variant:LOW:exon47/48:c.5301C>A:p.Thr1767=:PF00169,KIF1B:ENST00000377086:synonymous_variant:LOW:exon48/49:c.5301C>A:p.Thr1767=:PF00169	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	129401 [benign DISEASE=Pheochromocytoma,Neuroblastoma,not specified,Charcot-Marie-Tooth, Type 2];			rs11121552	0.2316	0.2794	1032,	0.0857,0.3447,0.2840,0.2953,0.2380	0.3006,0.0937	-0.4200			0.27,0.97	0.40					
chr1	10436892	10436892	-	AC	het	wt	het		QUAL=4747;DP=131,126,112;AF=0.81,0.52,0.31;MQM=59	KIF1B	3'UTR,intron	KIF1B:ENST00000263934:3_prime_UTR_variant:MODIFIER:exon47/47:c.*279_*280dup::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-1473_5409-1472dup::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*279_*280dup::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291586 [uncertain significance DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];		(AC)n			0.0586	36,							-0.01					
chr1	10436924	10436924	C	T	het	het	wt		QUAL=4747;DP=131,126,112;AF=0.81,0.52,0.31;MQM=59	KIF1B	3'UTR,intron	KIF1B:ENST00000263934:3_prime_UTR_variant:MODIFIER:exon47/47:c.*279C>T::,KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-1473C>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*279C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291594 [likely benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];		(AC)n	rs78490707	0.0403	0.0085	11,			-3.5950			0.04,0.22	-0.05					
chr1	10438006	10438006	A	T	het	wt	het		QUAL=1323;DP=82,72,54;AF=0.45,0.00,0.48;MQM=59	KIF1B	intron,3'UTR	KIF1B:ENST00000377081:intron_variant:MODIFIER:exon47/47:c.5409-391A>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*1361A>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291610 [likely benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];		AluSg	rs2847347	0.0182	0.0362	21,			0.2110			0.16,0.23	0.01					
chr1	10438687	10438687	C	T	het	het	het		QUAL=12136;DP=254,354,281;AF=0.56,0.51,0.51;MQM=60	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*227C>T::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*2042C>T::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291618 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];			rs1536262	0.5465	0.5499	4872,			-1.2450			0.03,0.16	-0.16					
chr1	10438892	10438892	G	A	het	het	het		QUAL=8836;DP=282,193,160;AF=0.54,0.52,0.57;MQM=60	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*432G>A::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*2247G>A::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291619 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];			rs1002076	0.3337	0.3305	1696,			0.4730			0.09,0.20	-0.09					
chr1	10440556	10440556	A	G	het	het	het		QUAL=8812;DP=324,225,182;AF=0.49,0.48,0.49;MQM=51	KIF1B	3'UTR	KIF1B:ENST00000377081:3_prime_UTR_variant:MODIFIER:exon48/48:c.*2096A>G::,KIF1B:ENST00000377086:3_prime_UTR_variant:MODIFIER:exon49/49:c.*3911A>G::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	291652 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];		AluSx	rs1138791	0.3488	0.3604	2003,			-1.5600			0.00,0.08	0.48					
chr1	10441664	10441664	T	C	het	het	het		QUAL=13580;DP=455,349,272;AF=0.53,0.50,0.44;MQM=60	KIF1B	downstream_gene	KIF1B:ENST00000263934:downstream_gene_variant:MODIFIER::::,KIF1B:ENST00000377081:downstream_gene_variant:MODIFIER::::,KIF1B:ENST00000377086:downstream_gene_variant:MODIFIER::::	605995 [KIF1B (confirmed) Charcot-Marie-Tooth disease,type 2A1,118210/Pheochromocytoma,171300/Neuroblastoma,susceptibility to,1,256700];	368794 [benign DISEASE=Pheochromocytoma,Neuroblastoma,Charcot-Marie-Tooth, Type 2];			rs3748581	0.5270	0.5291	4418,			0.2790			0.31,0.74	1.06					
chr1	11085004	11085004	-	TGTTT	het	hom	het		QUAL=16984;DP=383,272,258;AF=0.49,0.99,0.50;MQM=60	TARDBP,MASP2,RP4-635E18.8	downstream_gene,upstream_gene	TARDBP:ENST00000240185:downstream_gene_variant:MODIFIER::::,TARDBP:ENST00000315091:downstream_gene_variant:MODIFIER::::,MASP2:ENST00000400897:downstream_gene_variant:MODIFIER::::,TARDBP:ENST00000439080:downstream_gene_variant:MODIFIER::::,RP4-635E18.8:ENST00000607145:upstream_gene_variant:MODIFIER::::		291763 [benign DISEASE=Frontotemporal dementia,MASP2 deficiency,Amyotrophic Lateral Sclerosis, Dominant];			rs5772439	0.9151	0.8780	11922,							0.63					
chr1	11846092	11846092	-	T	hom	hom	hom		QUAL=4416;DP=114,51,37;AF=0.75,0.90,0.89;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4644dup::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4644dup::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3639+757dup::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292153 [benign DISEASE=Neural tube defects, folate-sensitive];			rs55740775	0.9513	0.9801	13575,							-0.20					
chr1	11846252	11846252	G	A	hom	het	het		QUAL=14846;DP=330,181,158;AF=1.00,0.54,0.50;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4485C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4485C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3639+906G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292158 [likely benign DISEASE=Neural tube defects, folate-sensitive];		Tigger15a	rs4846048	0.7065	0.6860	7437,			0.4870			0.00,0.12	0.20					
chr1	11846447	11846447	G	A	hom	hom	hom		QUAL=25207;DP=380,216,181;AF=1.00,1.00,1.00;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4290C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4290C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-998G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292160 [benign DISEASE=Neural tube defects, folate-sensitive];			rs4845884	0.9333	0.9390	13771,			-0.7990			0.00,0.10	0.08					
chr1	11846660	11846663	TTTT	-	hom	hom	hom		QUAL=1828;DP=78,39,31;AF=0.62,0.56,0.42;MQM=57	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*4074_*4077del::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*4074_*4077del::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-770_3640-767del::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292164 [likely benign DISEASE=Neural tube defects, folate-sensitive];		AluJr	rs55780505	0.7772	0.5158	3175,			0.3100				-0.07					
chr1	11847334	11847334	-	GAA	hom	het	het		QUAL=9662;DP=228,222,133;AF=0.97,0.41,0.58;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*3400_*3402dup::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*3400_*3402dup::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*3400_*3402dup::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon16/20:c.3640-108_3640-106dup::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292171 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs35134728	0.5701	0.5694	5183,							0.05					
chr1	11847759	11847759	C	T	hom	het	het		QUAL=11899;DP=193,292,241;AF=0.98,0.52,0.50;MQM=59	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2978G>A::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2978G>A::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*2978G>A::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon17/20:c.3746-171C>T::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292181 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs3737966	0.5585	0.5599	5073,			0.6900			0.30,0.29	0.32					
chr1	11848139	11848139	G	A	wt	het	het		QUAL=2672;DP=121,122,85;AF=0.01,0.48,0.55;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2598C>T::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*2598C>T::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*2598C>T::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon18/20:c.3920+35G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292191 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs11559040	0.1268	0.1691	351,	0.0339,0.0848,0.1037,0.1862,0.2666		-0.6770			0.09,0.19	0.14					
chr1	11848879	11848879	A	G	hom	hom	hom		QUAL=18803;DP=241,217,151;AF=1.00,1.00,1.00;MQM=60	MTHFR,C1orf167	3'UTR,intron	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1858T>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1858T>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1858T>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1858T>C::,C1orf167:ENST00000433342:intron_variant:MODIFIER:exon20/20:c.4245+76A>G::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292203 [benign DISEASE=Neural tube defects, folate-sensitive];			rs2077360	0.9305	0.9363	13702,			-0.5590			0.01,0.11	0.02					
chr1	11849447	11849447	A	G	hom	hom	hom		QUAL=17657;DP=146,226,188;AF=1.00,1.00,1.00;MQM=59	MTHFR,C1orf167	3'UTR,missense	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1290T>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*1290T>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*1290T>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*1290T>C::,C1orf167:ENST00000433342:missense_variant:MODERATE:exon21/21:c.4366A>G:p.Arg1456Gly:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292209 [benign DISEASE=Neural tube defects, folate-sensitive];			rs868014	0.9329	0.9874	13758,	0.7814,0.9877,1.0000,0.9990,0.9997		-4.9500	 , , , ,T	 , , , ,B	0.02,0.21	0.13	0.03				
chr1	11850365	11850365	T	G	hom	het	het		QUAL=18805;DP=311,383,349;AF=1.00,0.48,0.49;MQM=59	MTHFR	3'UTR	MTHFR:ENST00000376583:3_prime_UTR_variant:MODIFIER:exon12/12:c.*372A>C::,MTHFR:ENST00000376585:3_prime_UTR_variant:MODIFIER:exon13/13:c.*372A>C::,MTHFR:ENST00000376590:3_prime_UTR_variant:MODIFIER:exon12/12:c.*372A>C::,MTHFR:ENST00000376592:3_prime_UTR_variant:MODIFIER:exon11/11:c.*372A>C::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	292223 [likely benign DISEASE=Neural tube defects, folate-sensitive];			rs4846049	0.6284	0.6376	6407,			-0.6840			0.05,0.19	-0.07					
chr1	11851003	11851003	G	C	wt	het	het	off-target	QUAL=3861;DP=207,180,166;AF=0.00,0.43,0.48;MQM=60	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon11/11:c.1876-48C>G::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon12/12:c.1876-48C>G::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon11/11:c.1753-48C>G::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon10/10:c.1753-48C>G::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs3818762	0.2475	0.2611	873,	0.1337,0.1425,0.2148,0.2753,0.4136	0.2685,0.1543	-1.1340			0.00,0.02	-0.10					
chr1	11852300	11852300	C	T	wt	het	het	off-target	QUAL=4633;DP=171,209,197;AF=0.01,0.48,0.47;MQM=60	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon10/11:c.1755+35G>A::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon11/12:c.1755+35G>A::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon10/11:c.1632+35G>A::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon9/10:c.1632+35G>A::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs1476413	0.2512	0.2628	877,	0.1507,0.1394,0.2262,0.2738,0.4206	0.2607,0.1491	-1.1060			0.07,0.25	0.43					
chr1	11854457	11854457	G	A	hom	hom	hom		QUAL=18479;DP=119,264,204;AF=1.00,1.00,1.00;MQM=60	MTHFR	synonymous	MTHFR:ENST00000376583:synonymous_variant:LOW:exon8/12:c.1428C>T:p.Phe476=:,MTHFR:ENST00000376585:synonymous_variant:LOW:exon9/13:c.1428C>T:p.Phe476=:,MTHFR:ENST00000376590:synonymous_variant:LOW:exon8/12:c.1305C>T:p.Phe435=:,MTHFR:ENST00000376592:synonymous_variant:LOW:exon7/11:c.1305C>T:p.Phe435=:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	167306 [benign DISEASE=Neural tube defects, folate-sensitive,not specified];			rs4846051	0.9030	0.9755	13050,	0.6770,0.9820,0.9992,0.9984,0.9992	0.9970,0.6827	0.6310			0.47,0.83	0.70					
chr1	11854476	11854476	T	G	wt	het	het		QUAL=7156;DP=166,287,228;AF=0.01,0.54,0.54;MQM=60	MTHFR	missense	MTHFR:ENST00000376583:missense_variant:MODERATE:exon8/12:c.1409A>C:p.Glu470Ala:,MTHFR:ENST00000376585:missense_variant:MODERATE:exon9/13:c.1409A>C:p.Glu470Ala:,MTHFR:ENST00000376590:missense_variant:MODERATE:exon8/12:c.1286A>C:p.Glu429Ala:,MTHFR:ENST00000376592:missense_variant:MODERATE:exon7/11:c.1286A>C:p.Glu429Ala:	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];	3521 [drug response DISEASE=Schizophrenia, susceptibility to,Gastrointestinal stroma tumor,MTHFR deficiency, thermolabile type,Neural tube defects, folate-sensitive,not specified,fluorouracil, leucovorin, and oxaliplatin response - Efficacy,not provided];	CM981315 [CLASS=DFP MUT=ALT PHEN="Neural tube defect increased risk association with" GENE=MTHFR];		rs1801131	0.2494	0.2902	1085,	0.1579,0.1600,0.2192,0.3189,0.4112	0.3131,0.1550	3.7910	T,T,T,T	B,B,B,B	0.96,0.96	2.33	0.20				
chr1	11854755	11854755	G	A	hom	het	het	off-target	QUAL=3013;DP=70,54,57;AF=1.00,0.39,0.46;MQM=59	MTHFR	intron	MTHFR:ENST00000376583:intron_variant:MODIFIER:exon7/11:c.1289+31C>T::,MTHFR:ENST00000376585:intron_variant:MODIFIER:exon8/12:c.1289+31C>T::,MTHFR:ENST00000376590:intron_variant:MODIFIER:exon7/11:c.1166+31C>T::,MTHFR:ENST00000376592:intron_variant:MODIFIER:exon6/10:c.1166+31C>T::	607093 [MTHFR (provisional) Homocystinuria due to MTHFR deficiency,236250/Schizophrenia,susceptibility to,181500/Vascular disease,susceptibility to/Neural tube defects,susceptibility to,601634/Thromboembolism,susceptibility to,188050];				rs1994798	0.5793	0.6070	5178,	0.4319,0.7728,0.7605,0.5879,0.4683	0.5876,0.4346	-3.8760			0.03,0.15	-0.35					
chr1	12009955	12009955	C	T	het	het	het		QUAL=6842;DP=122,248,190;AF=0.46,0.49,0.53;MQM=60	PLOD1	synonymous	PLOD1:ENST00000196061:synonymous_variant:LOW:exon3/19:c.294C>T:p.Phe98=:,PLOD1:ENST00000376369:synonymous_variant:LOW:exon4/20:c.435C>T:p.Phe145=:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	255803 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];			rs7529452	0.2678	0.3311	1501,	0.0572,0.3535,0.3727,0.3166,0.4238	0.3119,0.0681	0.9490			0.69,0.83	0.69					
chr1	12009956	12009956	G	A	wt	wt	het		QUAL=2008;DP=146,243,188;AF=0.00,0.00,0.47;MQM=60	PLOD1	missense	PLOD1:ENST00000196061:missense_variant:MODERATE:exon3/19:c.295G>A:p.Ala99Thr:,PLOD1:ENST00000376369:missense_variant:MODERATE:exon4/20:c.436G>A:p.Ala146Thr:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	196247 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];	CM068658 [CLASS=DP MUT=ALT PHEN="Bone mineral density association with" GENE=PLOD1];		rs7551175	0.2995	0.2610	1526,	0.5540,0.0889,0.2520,0.1529,0.2124	0.1503,0.5347	1.4500	T,T	B,B	0.03,0.33	1.22	0.15				
chr1	12016957	12016957	T	G	wt	wt	het	off-target	QUAL=3761;DP=108,392,311;AF=0.00,0.00,0.50;MQM=60	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon6/18:c.644-17T>G::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon7/19:c.785-17T>G::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	384719 [benign DISEASE=not specified];			rs41307745	0.0769	0.0681	49,	0.0106,0.0250,0.1424,0.0614,0.1352	0.0541,0.0100	3.2240			0.64,0.22	0.40		-16.22% (10.55>8.84)			
chr1	12024235	12024235	C	T	het	het	het		QUAL=1152;DP=18,53,36;AF=0.56,0.53,0.39;MQM=60	PLOD1	synonymous	PLOD1:ENST00000196061:synonymous_variant:LOW:exon12/19:c.1206C>T:p.Asn402=:,PLOD1:ENST00000376369:synonymous_variant:LOW:exon13/20:c.1347C>T:p.Asn449=:	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];	255799 [benign DISEASE=Ehlers-Danlos syndrome, hydroxylysine-deficient,not specified,Cardiovascular phenotype];			rs1130529	0.3484	0.3624	2026,	0.2925,0.3687,0.3874,0.3279,0.4443	0.3210,0.2907	-1.0670			0.12,0.58	0.36					
chr1	12027204	12027204	C	T	het	het	hom	off-target	QUAL=9497;DP=42,211,205;AF=0.45,0.52,1.00;MQM=59	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon16/18:c.1755+56C>T::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon17/19:c.1896+56C>T::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];				rs2273293	0.5639	0.5225	4288,			-3.7710			0.01,0.05	-0.19					
chr1	12033113	12033113	A	G	het	het	hom	off-target	QUAL=11228;DP=132,264,209;AF=0.51,0.48,1.00;MQM=60	PLOD1	intron	PLOD1:ENST00000196061:intron_variant:MODIFIER:exon18/18:c.2028+59A>G::,PLOD1:ENST00000376369:intron_variant:MODIFIER:exon19/19:c.2169+59A>G::	153454 [PLOD1 (provisional) Ehlers-Danlos syndrome,kyphoscoliotic type,1,225400];				rs3737961	0.6498	0.5837	5474,			-0.4870			0.00,0.07	0.27					
chr1	12040203	12040203	A	G	het	het	hom	off-target	QUAL=901;DP=25,24,20;AF=0.44,0.46,1.00;MQM=60	PLOD1,MFN2	downstream_gene,upstream_gene	PLOD1:ENST00000196061:downstream_gene_variant:MODIFIER::::,MFN2:ENST00000235329:upstream_gene_variant:MODIFIER::::,MFN2:ENST00000444836:upstream_gene_variant:MODIFIER::::					rs2236053		0.5220	4265,			-0.9190			0.00,0.13	0.05					
chr1	12040324	12040324	A	G	het	het	hom		QUAL=4120;DP=30,123,101;AF=0.47,0.36,1.00;MQM=60	MFN2	5'UTR	MFN2:ENST00000444836:5_prime_UTR_variant:MODIFIER:exon1/18:c.-222A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292362 [benign DISEASE=Hereditary motor and sensory neuropathy,Ehlers-Danlos syndrome, hydroxylysine-deficient,Charcot-Marie-Tooth, Type 2];			rs2236054		0.5264	4364,			-0.9110			0.00,0.09	0.57					
chr1	12040479	12040479	T	C	het	het	hom		QUAL=5101;DP=51,128,113;AF=0.45,0.43,1.00;MQM=60	MFN2	5'UTR	MFN2:ENST00000235329:5_prime_UTR_variant:MODIFIER:exon1/19:c.-212T>C::,MFN2:ENST00000444836:5_prime_UTR_variant:MODIFIER:exon1/18:c.-67T>C::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292368 [benign DISEASE=Hereditary motor and sensory neuropathy,Ehlers-Danlos syndrome, hydroxylysine-deficient,Charcot-Marie-Tooth, Type 2];			rs2180183	0.6100	0.5525	4890,			-0.2970			0.00,0.05	0.56					
chr1	12062205	12062205	A	G	hom	hom	hom	off-target	QUAL=14516;DP=175,190,138;AF=0.99,0.99,0.99;MQM=59	MFN2	intron	MFN2:ENST00000235329:intron_variant:MODIFIER:exon11/18:c.1160+45A>G::,MFN2:ENST00000444836:intron_variant:MODIFIER:exon10/17:c.1160+45A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];				rs2236057	0.6579	0.6604	6770,	0.6473,0.5327,0.6752,0.6682,0.7031	0.6514,0.6480	-2.0590			0.01,0.11	0.03					
chr1	12071680	12071680	A	G	hom	hom	hom		QUAL=29203;DP=253,418,322;AF=0.99,1.00,0.99;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*58A>G::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*58A>G::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292381 [benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth, Type 2];			rs1042842	0.7324	0.7191	8125,		0.6556,0.8324	-0.8580			0.04,0.13	-0.22					
chr1	12072518	12072518	G	C	hom	hom	hom		QUAL=12743;DP=106,172,143;AF=0.99,1.00,1.00;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*896G>C::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*896G>C::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292393 [benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth, Type 2];			rs3088064	0.5441	0.5700	5095,			0.4850			0.22,0.22	0.02					
chr1	12072534	12072534	C	T	wt	wt	het		QUAL=1666;DP=102,189,145;AF=0.00,0.00,0.50;MQM=60	MFN2	3'UTR	MFN2:ENST00000235329:3_prime_UTR_variant:MODIFIER:exon19/19:c.*912C>T::,MFN2:ENST00000444836:3_prime_UTR_variant:MODIFIER:exon18/18:c.*912C>T::	608507 [MFN2 (confirmed) Charcot-Marie-Tooth disease,axonal,type 2A2A,609260/Hereditary motor and sensory neuropathy VIA,601152/Charcot-Marie-Tooth disease,axonal,type 2A2B,617087];	292394 [likely benign DISEASE=Hereditary motor and sensory neuropathy,Charcot-Marie-Tooth, Type 2];			rs14305	0.0843	0.0545	53,			0.1270			0.12,0.31	0.43					
chr1	16370428	16370432	GGGGG	-	wt	hom	wt	off-target	QUAL=48;DP=102,4,145;AF=0.00,0.75,0.50;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon1/19:c.-8+61_-8+65del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs140434107	0.9447	0.5133	2037,			1.3540				0.09					
chr1	16371067	16371067	G	T	het	hom	hom		QUAL=234;DP=4,5,1;AF=0.75,1.00,1.00;MQM=60	CLCNKB	missense	CLCNKB:ENST00000375679:missense_variant:MODERATE:exon2/20:c.80G>T:p.Arg27Leu:	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447107 [benign DISEASE=not specified];			rs2015352		0.6271	4748,	0.2847,0.7316,0.6346,0.6333,0.6876	0.6422,0.3000	-0.4670	D	B	0.14,0.92	2.69	0.30				
chr1	16372003	16372003	G	C	het	hom	het	off-target	QUAL=6416;DP=54,148,129;AF=0.41,1.00,0.48;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon2/19:c.101-50G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6604910	0.5665	0.6361	4785,	0.2673,0.7372,0.6808,0.6382,0.7116	0.6429,0.2835	0.6820			0.01,0.14	0.16					
chr1	16372971	16372971	G	A	hom	hom	hom	off-target	QUAL=12404;DP=81,182,142;AF=1.00,1.00,1.00;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon3/19:c.230-59G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs2014841	0.7404	0.6927	8052,			-0.2720			0.02,0.13	-0.01					
chr1	16373124	16373124	A	G	hom	hom	hom		QUAL=23051;DP=179,312,248;AF=0.98,1.00,1.00;MQM=59	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon4/20:c.324A>G:p.Ser108=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447104 [benign DISEASE=not specified];			rs5257	0.7404	0.8123	8028,	0.3761,0.9003,0.9891,0.8095,0.8739	0.8117,0.3997	-4.7220			0.03,0.24	-0.32					
chr1	16373200	16373202	CTT	-	hom	hom	het	off-target	QUAL=9995;DP=121,222,148;AF=0.99,1.00,0.50;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon4/19:c.358+44_358+46del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs35820664	0.7234	0.7864	7421,	0.3522,0.8890,0.9890,0.7807,0.8445	0.7798,0.3762	0.5420				0.87					
chr1	16374533	16374533	G	C	hom	hom	hom		QUAL=383;DP=5,3,5;AF=1.00,1.00,1.00;MQM=60	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon5/20:c.492G>C:p.Gly164=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447105 [benign DISEASE=not specified];			rs2014562	0.8940	0.9317	12455,	0.7566,0.9581,0.9997,0.9438,0.9276	0.9364,0.7653	-0.3820			0.06,0.95	0.27					
chr1	16374994	16374994	C	T	hom	hom	hom		QUAL=17810;DP=154,245,203;AF=0.99,1.00,1.00;MQM=46	CLCNKB	splice_region&intron	CLCNKB:ENST00000375679:splice_region_variant&intron_variant:LOW:exon6/19:c.577-5C>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	381050 [benign/likely benign DISEASE=not specified];			rs1889788,rs34666902	0.7386	0.8106	7997,	0.3734,0.8993,0.9890,0.8077,0.8731		-0.3170			0.02,0.22	-0.13		-2.80% (4.28>4.16)		0.000/0.000	
chr1	16375063	16375063	C	G	hom	hom	hom		QUAL=16997;DP=185,216,173;AF=0.99,1.00,1.00;MQM=52	CLCNKB	missense	CLCNKB:ENST00000375679:missense_variant:MODERATE:exon7/20:c.641C>G:p.Ala214Gly:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	504916 [benign DISEASE=not specified];			rs1889789,rs45612832	0.8273	0.9074	10949,	0.5567,0.9396,0.9997,0.9257,0.9253		-0.0390	T	B	0.06,0.42	0.74	0.22				
chr1	16375064	16375064	A	C	hom	hom	hom		QUAL=16997;DP=185,216,173;AF=0.99,1.00,1.00;MQM=52	CLCNKB	synonymous	CLCNKB:ENST00000375679:synonymous_variant:LOW:exon7/20:c.642A>C:p.Ala214=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	504915 [benign DISEASE=not specified];			rs1889790,rs45575235		0.9074	10949,	0.5567,0.9395,0.9997,0.9256,0.9253		-2.2040			0.07,0.28	0.55					
chr1	16375210	16375210	G	A	het	hom	wt	off-target	QUAL=4190;DP=97,100,103;AF=0.48,0.99,0.00;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon7/19:c.655+133G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs9633514	0.3570	0.2949	1622,			-0.2940			0.09,0.19	0.36					
chr1	16375354	16375354	C	T	hom	hom	hom		QUAL=18577;DP=165,236,202;AF=1.00,1.00,1.00;MQM=59	CLCNKB	5'UTR,intron	CLCNKB:ENST00000375667:5_prime_UTR_variant:MODIFIER:exon1/13:c.-113C>T::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon7/19:c.656-261C>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];			MIR	rs9442227	0.7274	0.6829	7837,			-0.1220			0.08,0.21	0.56					
chr1	16376191	16376191	C	T	hom	hom	hom		QUAL=25479;DP=182,405,313;AF=0.99,1.00,1.00;MQM=44	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon2/13:c.353C>T:p.Ala118Val:PF00654,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon9/20:c.860C>T:p.Ala287Val:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447108 [benign DISEASE=not specified];			rs7367494,rs34188929	0.8299	0.9247	11085,	0.5579,0.9602,0.9989,0.9475,0.9333		-0.3350	T,T	B,B	0.02,0.12	-0.56	0.22				
chr1	16376230	16376230	-	T	hom	hom	hom	off-target	QUAL=22542;DP=18,441,341;AF=0.67,0.95,0.95;MQM=51	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+33_359+34insT::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+33_866+34insT::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs59006537		0.9268	10546,	0.4387,0.9463,0.9983,0.9566,0.9478	0.9087,0.5279					-0.08					
chr1	16376232	16376232	A	T	hom	hom	hom	off-target	QUAL=22542;DP=18,441,341;AF=0.67,0.95,0.95;MQM=51	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+35A>T::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+35A>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs59924562	0.7542	0.9275	10563,	0.4546,0.9471,0.9984,0.9566,0.9471		-2.8490			0.01,0.08	-0.18					
chr1	16376239	16376239	C	-	hom	hom	hom	off-target	QUAL=24456;DP=79,440,340;AF=1.00,0.99,0.98;MQM=52	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.359+47del::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.866+47del::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs34589727	0.8301	0.9174	10535,	0.4259,0.9421,0.9987,0.9495,0.9351		-0.1430				-0.08					
chr1	16376278	16376278	G	A	hom	hom	hom	off-target	QUAL=30453;DP=138,501,364;AF=0.99,1.00,1.00;MQM=57	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon2/12:c.360-32G>A::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon9/19:c.867-32G>A::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7365182	0.8279	0.9211	11151,	0.5504,0.9550,0.9999,0.9457,0.9312	0.9355,0.5729	1.2090			0.08,0.18	-0.05					
chr1	16376319	16376319	T	C	hom	hom	hom		QUAL=32761;DP=182,484,361;AF=1.00,1.00,1.00;MQM=59	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon3/13:c.369T>C:p.Cys123=:PF00654,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon10/20:c.876T>C:p.Cys292=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	377683 [benign DISEASE=not specified];			rs7368151	0.8301	0.9173	11243,	0.5553,0.9490,0.9998,0.9431,0.9268	0.9353,0.5803	-4.5300			0.03,0.87	-0.25					
chr1	16376458	16376458	T	C	hom	hom	hom	off-target	QUAL=16879;DP=125,258,183;AF=0.99,1.00,1.00;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon3/12:c.461+47T>C::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon10/19:c.968+47T>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7368166		0.9137	10821,	0.5488,0.9461,0.9985,0.9398,0.9197	0.9303,0.5531	-4.4690			0.00,0.06	0.23					
chr1	16378649	16378649	C	G	het	wt	het	off-target	QUAL=483;DP=19,11,19;AF=0.58,0.00,0.68;MQM=60	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon7/12:c.902-44C>G::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon14/19:c.1409-44C>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs2297726	0.1625	0.1725	412,	0.0701,0.1583,0.2983,0.1706,0.1630	0.1670,0.0731	0.0970			0.05,0.21	0.33					
chr1	16378739	16378739	G	A	wt	wt	het		QUAL=107;DP=27,16,22;AF=0.00,0.00,0.36;MQM=60	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon8/13:c.948G>A:p.Ala316=:PF00654,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon15/20:c.1455G>A:p.Ala485=:PF00654	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs34652156	0.0302	0.0369	32,	0.0580,0.0120,0.0000,0.0273,0.0295	0.0301,0.0572	-2.6720			0.05,0.21	-0.50					
chr1	16380196	16380196	T	C	hom	hom	hom		QUAL=28212;DP=294,369,251;AF=1.00,1.00,1.00;MQM=51	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon9/13:c.1178T>C:p.Met393Thr:PF00571,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon16/20:c.1685T>C:p.Met562Thr:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447094 [benign DISEASE=not specified];			rs5253	0.8383	0.9354	12314,	0.6839,0.9477,0.8066,0.9843,0.9315	0.9844,0.7006	-0.9230	T,T	B,B	0.00,0.10	0.12	0.28				
chr1	16380243	16380243	A	G	hom	hom	het		QUAL=15362;DP=131,311,232;AF=1.00,0.99,0.42;MQM=48	CLCNKB	missense	CLCNKB:ENST00000375667:missense_variant:MODERATE:exon9/13:c.1225A>G:p.Lys409Glu:PF00571,CLCNKB:ENST00000375679:missense_variant:MODERATE:exon16/20:c.1732A>G:p.Lys578Glu:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447096 [benign DISEASE=not specified];	CM1514575 [CLASS=DM? MUT=ALT PHEN="Migraine without aura" GENE=CLCNKB];		rs2275166	0.7017	0.7160	7998,	0.7984,0.5168,0.7943,0.6598,0.5829	0.6503,0.7994	0.8530	T,T	B,B	0.01,0.19	1.19	0.16				
chr1	16380252	16380252	C	T	hom	hom	het		QUAL=14358;DP=122,302,218;AF=1.00,1.00,0.43;MQM=48	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon9/13:c.1234C>T:p.Leu412=:PF00571,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon16/20:c.1741C>T:p.Leu581=:PF00571	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	447097 [benign DISEASE=not specified];			rs2275167	0.6136	0.6412	6404,	0.5758,0.4916,0.7888,0.6450,0.5284	0.6278,0.5792	0.5590			0.14,0.85	1.39					
chr1	16382877	16382877	A	G	hom	hom	hom	off-target	QUAL=11602;DP=50,203,147;AF=1.00,1.00,0.99;MQM=59	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon11/12:c.1420-40A>G::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon18/19:c.1930-40A>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs7517792	0.7841	0.7960	8650,	0.7050,0.8851,0.8072,0.7871,0.8421	0.7907,0.7059	-2.5310			0.01,0.13	0.12					
chr1	16383329	16383329	-	C	wt	hom	het	off-target	QUAL=125;DP=4,9,26;AF=1.00,0.89,0.27;MQM=46	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon12/12:c.1507-29dup::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon19/19:c.2017-29dup::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs138507185		0.6237	5165,							0.01					
chr1	16383336	16383336	G	C	hom	hom	het	off-target	QUAL=125;DP=4,9,26;AF=1.00,0.89,0.27;MQM=39	CLCNKB	intron	CLCNKB:ENST00000375667:intron_variant:MODIFIER:exon12/12:c.1507-28G>C::,CLCNKB:ENST00000375679:intron_variant:MODIFIER:exon19/19:c.2017-28G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs12746138	0.7147	0.7060	5840,	0.4282,0.8359,0.7612,0.6962,0.7947		-1.1840			0.00,0.06	-0.65					
chr1	16383402	16383402	C	T	het	wt	wt		QUAL=694;DP=259,143,140;AF=0.27,0.07,0.00;MQM=34	CLCNKB	synonymous	CLCNKB:ENST00000375667:synonymous_variant:LOW:exon13/13:c.1545C>T:p.Ala515=:,CLCNKB:ENST00000375679:synonymous_variant:LOW:exon20/20:c.2055C>T:p.Ala685=:	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6698427		0.0849	0,	0.0130,0.0031,0.0135,0.0013,0.0026		0.3830			0.26,0.96	1.07					
chr1	16383448	16383448	A	C	het	hom	hom		QUAL=15892;DP=223,289,241;AF=0.70,0.89,1.00;MQM=40	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*37A>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*37A>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs10803415	0.9010	0.9058	5773,	0.8408,0.9244,0.6927,0.9419,0.8839		-1.8510			0.00,0.05	0.29					
chr1	16383547	16383547	T	C	wt	het	wt		QUAL=531;DP=233,597,398;AF=0.05,0.19,0.00;MQM=31	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*136T>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*136T>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057839		0.2200	4,			0.0660			0.00,0.06	0.30					
chr1	16383574	16383574	A	T	het	het	wt		QUAL=887;DP=245,617,380;AF=0.13,0.20,0.00;MQM=32	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*163A>T::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*163A>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057841		0.2504	0,			0.4380			0.07,0.16	0.12					
chr1	16383581	16383581	G	T	het	het	het		QUAL=19836;DP=246,619,382;AF=0.84,0.80,0.52;MQM=37	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*170G>T::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*170G>T::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057844		0.4992	1842,			-1.3730			0.03,0.14	-0.11					
chr1	16383605	16383605	A	G	het	het	het		QUAL=19759;DP=198,648,402;AF=0.74,0.77,0.53;MQM=37	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*194A>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*194A>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057845		0.4932	1661,			-0.5960			0.01,0.17	0.33					
chr1	16383668	16383668	T	G	hom	hom	hom		QUAL=32690;DP=170,659,360;AF=0.99,1.00,1.00;MQM=41	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*257T>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*257T>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs6660218	1.0000	1.0000	15481,	1.0000,1.0000,0.9999,0.9999,1.0000		0.1210			0.00,0.08	0.08					
chr1	16383682	16383682	G	C	het	het	wt		QUAL=4389;DP=219,649,322;AF=0.19,0.35,0.00;MQM=41	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*271G>C::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*271G>C::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];	402540 [benign DISEASE=not specified];			rs1057854		0.3304	49,	0.4016,0.2172,0.4241,0.3038,0.2889		-3.2740			0.01,0.12	-0.29					
chr1	16383742	16383742	C	G	het	het	hom		QUAL=18344;DP=347,516,224;AF=0.55,0.53,1.00;MQM=57	CLCNKB	3'UTR	CLCNKB:ENST00000375667:3_prime_UTR_variant:MODIFIER:exon13/13:c.*331C>G::,CLCNKB:ENST00000375679:3_prime_UTR_variant:MODIFIER:exon20/20:c.*331C>G::	602023 [CLCNKB (confirmed) Bartter syndrome,type 3,607364/Bartter syndrome,type 4b,digenic,613090];				rs1057857		0.6426	3983,	0.5903,0.6982,0.4933,0.6545,0.6181		-0.3020			0.04,0.20	0.29					
chr1	16383854	16383854	A	G	het	het	wt	off-target	QUAL=616;DP=104,110,56;AF=0.36,0.17,0.00;MQM=38	FAM131C,CLCNKB	downstream_gene	FAM131C:ENST00000375662:downstream_gene_variant:MODIFIER::::,CLCNKB:ENST00000375667:downstream_gene_variant:MODIFIER::::,CLCNKB:ENST00000375679:downstream_gene_variant:MODIFIER::::					rs749928769		0.0227	1,			-0.5780			0.00,0.11	0.02					
chr1	17312743	17312743	C	T	het	het	hom		QUAL=709;DP=17,25,19;AF=0.41,0.44,0.95;MQM=60	ATP13A2,RP1-37C10.3	synonymous,missense,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon29/29:c.3516G>A:p.Pro1172=:,ATP13A2:ENST00000341676:missense_variant:MODERATE:exon27/27:c.3214G>A:p.Ala1072Thr:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7136C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon29/29:c.3501G>A:p.Pro1167=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128475 [benign DISEASE=Parkinson disease 9,not specified];			rs3170740	0.3313	0.4714	2943,	0.2016,0.4861,0.2957,0.5289,0.4627	0.5255,0.2168	-2.5490	 ,T, , 	 ,B, , 	0.02,0.13	-0.26	0.24				
chr1	17313157	17313157	G	A	het	het	hom	off-target	QUAL=9601;DP=83,297,216;AF=0.39,0.50,1.00;MQM=60	ATP13A2,RP1-37C10.3	intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:intron_variant:MODIFIER:exon27/28:c.3236-30C>T::,ATP13A2:ENST00000341676:intron_variant:MODIFIER:exon26/26:c.3103+143C>T::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7550G>A::,ATP13A2:ENST00000452699:intron_variant:MODIFIER:exon27/28:c.3221-30C>T::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];				rs2076605	0.3468	0.4724	2967,	0.2184,0.4848,0.2981,0.5242,0.4772	0.5195,0.2344	1.8880			0.04,0.13	0.16					
chr1	17313245	17313256	CCCAGGGCTCCT	-	het	het	wt	off-target	QUAL=2154;DP=59,210,167;AF=0.39,0.50,0.00;MQM=60	ATP13A2,RP1-37C10.3	intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:intron_variant:MODIFIER:exon27/28:c.3235+44_3235+55del::,ATP13A2:ENST00000341676:intron_variant:MODIFIER:exon26/26:c.3103+44_3103+55del::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7641_187+7652del::,ATP13A2:ENST00000452699:intron_variant:MODIFIER:exon27/28:c.3220+44_3220+55del::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];				rs143483351	0.3059	0.2361	914,			1.0320				0.36					
chr1	17313343	17313343	G	A	het	het	hom		QUAL=10657;DP=92,282,200;AF=0.48,0.49,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon27/29:c.3192C>T:p.Ala1064=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon26/27:c.3060C>T:p.Ala1020=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7736G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon27/29:c.3177C>T:p.Ala1059=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128473 [benign DISEASE=Parkinson disease 9,not specified];			rs9435659	0.3385	0.4669	2965,	0.1868,0.4792,0.2913,0.5224,0.4729	0.5234,0.2077	-0.5550			0.07,0.19	-0.07					
chr1	17313454	17313454	G	A	het	het	wt		QUAL=2298;DP=59,177,138;AF=0.47,0.44,0.00;MQM=60	ATP13A2,RP1-37C10.3	splice_region&intron,intron&non_coding_transcript	ATP13A2:ENST00000326735:splice_region_variant&intron_variant:LOW:exon26/28:c.3084-3C>T::,ATP13A2:ENST00000341676:splice_region_variant&intron_variant:LOW:exon25/26:c.2952-3C>T::,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+7847G>A::,ATP13A2:ENST00000452699:splice_region_variant&intron_variant:LOW:exon26/28:c.3069-3C>T::	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128471 [benign DISEASE=Parkinson disease 9,not specified];			rs7531163	0.3065	0.2811	989,	0.1686,0.3598,0.5507,0.2392,0.2313	0.2392,0.1686	0.9070			0.66,0.95	1.03		+6.53% (9.29>9.90)		0.001/0.100	
chr1	17313654	17313654	C	T	het	het	hom		QUAL=10644;DP=66,280,245;AF=0.52,0.48,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon26/29:c.2970G>A:p.Val990=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon25/27:c.2838G>A:p.Val946=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+8047C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon26/29:c.2955G>A:p.Val985=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128470 [benign DISEASE=Parkinson disease 9,not specified];			rs761421	0.3462	0.4670	2984,	0.2153,0.4798,0.2851,0.5201,0.4729	0.5220,0.2374	-0.9690			0.25,0.72	1.03					
chr1	17314702	17314702	C	T	het	het	wt		QUAL=11015;DP=281,583,493;AF=0.48,0.51,0.01;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon25/29:c.2790G>A:p.Ser930=:,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon24/27:c.2658G>A:p.Ser886=:,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+9095C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon25/29:c.2775G>A:p.Ser925=:	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128468 [benign DISEASE=Parkinson disease 9,not specified];			rs3738815	0.2909	0.2488	846,	0.1505,0.3344,0.5508,0.1934,0.2224	0.1927,0.1496	-2.3320			0.06,0.15	0.21					
chr1	17314942	17314942	G	A	het	het	hom		QUAL=14038;DP=300,321,262;AF=0.50,0.45,0.99;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon24/29:c.2637C>T:p.Gly879=:PF12710,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon23/27:c.2505C>T:p.Gly835=:PF12710,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.187+9335G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon24/29:c.2622C>T:p.Gly874=:PF12710	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128466 [benign DISEASE=Parkinson disease 9,not specified];			rs9435662	0.3387	0.4650	2930,	0.1860,0.4781,0.2909,0.5192,0.4726	0.5222,0.2070	-4.7600			0.06,0.67	1.18					
chr1	17319011	17319011	G	A	het	het	hom		QUAL=6537;DP=81,152,126;AF=0.48,0.48,1.00;MQM=60	ATP13A2,RP1-37C10.3	synonymous,intron&non_coding_transcript	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon17/29:c.1815C>T:p.Pro605=:PF12710,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon17/27:c.1800C>T:p.Pro600=:PF12710,RP1-37C10.3:ENST00000446261:intron_variant&non_coding_transcript_variant:MODIFIER:exon1/1:n.188-12127G>A::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon17/29:c.1800C>T:p.Pro600=:PF12710	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	128465 [benign DISEASE=Parkinson disease 9,not specified];			rs2076603	0.4485	0.5576	4685,	0.4421,0.5458,0.2882,0.6259,0.5186	0.6323,0.4462	0.1640			0.51,0.95	1.26					
chr1	17331268	17331268	C	T	wt	wt	het		QUAL=642;DP=135,121,74;AF=0.00,0.00,0.41;MQM=60	ATP13A2,RP1-37C10.3	synonymous,non_coding_transcript_exon	ATP13A2:ENST00000326735:synonymous_variant:LOW:exon5/29:c.396G>A:p.Ala132=:PF12409,ATP13A2:ENST00000341676:synonymous_variant:LOW:exon5/27:c.396G>A:p.Ala132=:PF12409,RP1-37C10.3:ENST00000446261:non_coding_transcript_exon_variant:MODIFIER:exon2/2:n.318C>T::,ATP13A2:ENST00000452699:synonymous_variant:LOW:exon5/29:c.396G>A:p.Ala132=:PF12409	610513 [ATP13A2 (confirmed) Kufor-Rakeb syndrome,606693/Spastic paraplegia 78,autosomal recessive,617225];	293803 [uncertain significance DISEASE=Parkinson disease 9];			rs140631323		0.0001	0,	0.0000,0.0001,0.0000,0.0001,0.0002	0.0001,0.0000	-4.6690			0.02,0.09	0.10					COSM4946978,COSM80893
chr1	19198064	19198064	T	G	het	het	wt		QUAL=3438;DP=96,185,149;AF=0.52,0.47,0.00;MQM=59	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*262A>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1275A>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2893A>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1275A>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1275A>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294333 [likely benign DISEASE=Hyperprolinemia];			rs1138333	0.1793	0.2341	879,			1.6090			0.00,0.14	0.39					
chr1	19198100	19198100	C	G	het	het	wt		QUAL=3379;DP=94,166,144;AF=0.54,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*226G>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1239G>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2857G>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1239G>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1239G>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294334 [likely benign DISEASE=Hyperprolinemia];			rs1138328	0.1651	0.2276	849,			0.1130			0.00,0.11	0.10					
chr1	19198141	19198141	T	C	het	het	wt		QUAL=3385;DP=120,146,139;AF=0.53,0.48,0.00;MQM=60	ALDH4A1,RP13-279N23.2	3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:3_prime_UTR_variant:MODIFIER:exon16/16:c.*185A>G::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1198A>G::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2816A>G::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*1198A>G::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*1198A>G::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294336 [likely benign DISEASE=Hyperprolinemia];			rs7366541	0.1799	0.2342	887,			-1.2020			0.06,0.15	0.12					
chr1	19198414	19198414	G	A	het	het	wt		QUAL=4514;DP=168,196,168;AF=0.48,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-130C>T::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*925C>T::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2543C>T::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*925C>T::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*925C>T::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294341 [likely benign DISEASE=Hyperprolinemia];			rs1140477	0.1935	0.2423	899,			0.5800			0.12,0.17	0.09					
chr1	19198418	19198418	C	T	het	het	wt		QUAL=4514;DP=168,196,168;AF=0.48,0.49,0.00;MQM=60	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-134G>A::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*921G>A::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2539G>A::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*921G>A::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*921G>A::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294342 [likely benign DISEASE=Hyperprolinemia];			rs1138269	0.1933	0.2424	899,			0.1330			0.06,0.16	0.12					
chr1	19198576	19198576	A	G	hom	hom	hom		QUAL=29665;DP=367,313,238;AF=1.00,0.99,1.00;MQM=59	ALDH4A1,RP13-279N23.2	intron,3'UTR,intron&NMD_transcript	ALDH4A1:ENST00000290597:intron_variant:MODIFIER:exon15/15:c.*42-292T>C::,ALDH4A1:ENST00000375341:3_prime_UTR_variant:MODIFIER:exon15/15:c.*763T>C::,RP13-279N23.2:ENST00000494072:intron_variant&NMD_transcript_variant:MODIFIER:exon22/26:c.*1742+2381T>C::,ALDH4A1:ENST00000538309:3_prime_UTR_variant:MODIFIER:exon15/15:c.*763T>C::,ALDH4A1:ENST00000538839:3_prime_UTR_variant:MODIFIER:exon14/14:c.*763T>C::	606811 [ALDH4A1 (provisional) Hyperprolinemia,type II,239510];	294344 [likely benign DISEASE=Hyperprolinemia];			rs1138267		0.6397	6452,			-5.8090			0.01,0.12	-0.16					
chr22	51065524	51065524	C	A	wt	het	wt	off-target	QUAL=261;DP=18,24,21;AF=0.00,0.71,0.00;MQM=60	ARSA	intron	ARSA:ENST00000216124:intron_variant:MODIFIER:exon2/7:c.466-44G>T::,ARSA:ENST00000356098:intron_variant:MODIFIER:exon3/8:c.466-44G>T::,ARSA:ENST00000395619:intron_variant:MODIFIER:exon3/8:c.466-44G>T::,ARSA:ENST00000395621:intron_variant:MODIFIER:exon3/8:c.466-44G>T::,ARSA:ENST00000453344:intron_variant:MODIFIER:exon2/7:c.208-44G>T::,ARSA:ENST00000547307:intron_variant:MODIFIER:exon2/7:c.460-44G>T::,ARSA:ENST00000547805:intron_variant:MODIFIER:exon3/8:c.460-44G>T::	607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];				rs6151413	0.0086	0.0151	1,	0.0037,0.0038,0.0072,0.0176,0.0097	0.0155,0.0056	-1.5180			0.05,0.14	-0.01					
chr22	51066537	51066537	G	A	wt	het	wt		QUAL=851;DP=137,76,60;AF=0.00,0.54,0.00;MQM=60	ARSA	5'UTR	ARSA:ENST00000216124:5_prime_UTR_variant:MODIFIER:exon1/8:c.-330C>T::,ARSA:ENST00000356098:5_prime_UTR_variant:MODIFIER:exon1/9:c.-177C>T::,ARSA:ENST00000395619:5_prime_UTR_variant:MODIFIER:exon1/9:c.-132C>T::,ARSA:ENST00000395621:5_prime_UTR_variant:MODIFIER:exon1/9:c.-225C>T::,ARSA:ENST00000453344:5_prime_UTR_variant:MODIFIER:exon1/8:c.-198C>T::,ARSA:ENST00000547307:5_prime_UTR_variant:MODIFIER:exon1/8:c.-336C>T::,ARSA:ENST00000547805:5_prime_UTR_variant:MODIFIER:exon1/9:c.-231C>T::	607574 [ARSA (confirmed) Metachromatic leukodystrophy,250100];	342248 [uncertain significance DISEASE=Metachromatic leukodystrophy];			rs558023516	0.0012	0.0066	0,			-2.1550			0.01,0.07	0.29					
chrX	154064580	154064580	T	C	hom	hom	hom		QUAL=10757;DP=114,91,124;AF=1.00,1.00,0.99;MQM=60	F8	3'UTR	F8:ENST00000330287:3_prime_UTR_variant:MODIFIER:exon5/5:c.*1292A>G::,F8:ENST00000360256:3_prime_UTR_variant:MODIFIER:exon26/26:c.*1292A>G::	300841 [F8 (confirmed) Hemophilia A,306700];				rs1396947	0.9926	0.9949	6855,7690			-0.8180			0.00,0.04	0.28					
chrX	154488153	154488153	C	T	hom	wt	het		QUAL=7463;DP=181,78,101;AF=1.00,0.00,0.52;MQM=60	RAB39B	3'UTR	RAB39B:ENST00000369454:3_prime_UTR_variant:MODIFIER:exon2/2:c.*1935G>A::	300774 [RAB39B (confirmed) Mental retardation,X-linked 72,300271/Waisman syndrome,311510];	368130 [likely benign DISEASE=Non-syndromic X-linked intellectual disability];			rs782447828	0.0005	0.0011	0,10			-1.1200			0.01,0.13	-0.39					
chrMT	16298	16298	T	C	hom	wt	hom		QUAL=331460;DP=6107,4794,4214;AF=0.99,0.00,0.99;MQM=59	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs148377232															
chrMT	16519	16519	T	C	hom	wt	hom		QUAL=371189;DP=7009,4954,4518;AF=1.00,0.01,1.00;MQM=58	MT-ND4,MT-ND5,MT-ND6,MT-CYB,MT-TH,MT-TS2,MT-TL2,MT-TE,MT-TT,MT-TP	downstream_gene,upstream_gene	MT-ND4:ENST00000361381:downstream_gene_variant:MODIFIER::::,MT-ND5:ENST00000361567:downstream_gene_variant:MODIFIER::::,MT-ND6:ENST00000361681:upstream_gene_variant:MODIFIER::::,MT-CYB:ENST00000361789:downstream_gene_variant:MODIFIER::::,MT-TH:ENST00000387441:downstream_gene_variant:MODIFIER::::,MT-TS2:ENST00000387449:downstream_gene_variant:MODIFIER::::,MT-TL2:ENST00000387456:downstream_gene_variant:MODIFIER::::,MT-TE:ENST00000387459:upstream_gene_variant:MODIFIER::::,MT-TT:ENST00000387460:downstream_gene_variant:MODIFIER::::,MT-TP:ENST00000387461:upstream_gene_variant:MODIFIER::::					rs3937033															
